Table 1.
Participants' characteristics.
| All patients (n = 44) | Stroke group (n = 22, Group 1) | Control group (n = 22, Group 2) | P-value (Group 1 vs. Group 2) | |
|---|---|---|---|---|
| Gender, female/male | 19/25 | 7/15 | 12/10 | n.s. |
| Age (years), mean ± SD | 63.8 ± 7.0 | 62.4 ± 6.7 | 65.2 ± 7.1 | n.s. |
| Body mass index, mean ± SD, kg/m2 | 28 ± 7 | 27 ± 5 | 28 ± 5 | n.s. |
| ANTICOAGULANT THERAPY | ||||
| ASA (100 mg), n (%) | 18 (41) | 15 (68) | 3 (14) | 0.0003 |
| Clopidogrel (75 mg), n (%) | 6 (14) | 6 (27) | 0 (0) | 0.0110 |
| Antidiabetic therapy, n (%) | 2 (5) | 1 (4) | 1 (4) | n.s. |
| Antihypertensive therapy, n (%) | 23 (52) | 16 (73) | 7 (32) | 0.0074 |
| Previous vascular events, n (%) (venous thromboembolism, MCI) | 2 (5) | 2 (10) | 0 (0) | <0.0001 |
| VASCULAR RISK FACTORS | ||||
| Arterial hypertension, n (%) | 24 (55) | 18 (82) | 6 (27) | 0.0003 |
| Dyslipidemia, n (%) | 21 (48) | 16 (73) | 5 (23) | 0.0011 |
| Diabetes mellitus, n (%) | 2 (5) | 1 (5) | 1 (5) | n.s. |
| Nicotine usage | 4 (9) | 3 (14) | 1 (5) | n.s. |
| Obesity > grade 1, n (%) | 4 (9) | 3 (14) | 1 (5) | n.s. |
| Atrial fibrillation, n (%) | 4 (9) | 4 (18) | 0 (0) | n.s. |
| NIHSS at baseline, median (range) | 0 (0–3) | 1 (0–3) | 0 (0) | <0.0001 |
A total of 44 individuals performed a sit-to-stand test. Group 1 comprised of 22 older patients who had recovered from ischemic stroke, 22 healthy age-matched controls served as controls (Group 2). P-values were calculated by means of the Fischer's exact test. ASA, acetylsalicylic acid; MCI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale.